Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study
Abstract Background Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. This study aimed to evaluate the efficacy and safet...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2021-01-01
|
| Series: | Egyptian Liver Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43066-021-00079-7 |